CytoMed Therapeutics Expands into Autoimmune Diseases Following Recent Cord Blood Bank Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 28 2025
0mins
Source: Newsfilter
Company Overview: CytoMed Therapeutics, a Singapore-based biopharmaceutical company, focuses on developing affordable donor-derived cell-based immunotherapies for various cancers and has successfully expanded clinical-scale natural killer (NK) cells from long-preserved cord blood units.
New Business Structure: The company is reorganizing to create LongevityBank, which will focus on autologous therapies using personalized cellular banking services, while CytoMed will concentrate on allogeneic therapies that are already in clinical trials.
Cord Blood Bank Acquisition: CytoMed's acquisition of a licensed cord blood bank in Malaysia allows access to valuable cord blood resources, enhancing the development of new therapeutics for autoimmune diseases and cancers.
Future Growth Plans: The company aims to spin off LongevityBank as an independent entity, leveraging its cost-effective R&D infrastructure to produce both autologous and allogeneic cell therapies, with expectations of positive revenue contributions from the restarted banking business.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on GDTC
About GDTC
CytoMed Therapeutics Limited is a biopharmaceutical company. It is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The Company also has the allogeneic gamma delta T cell technology, namely TCB-002.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CytoMed Addresses False Claims, Reaffirms Research Progress
- Research Progress Statement: CytoMed is conducting its first CAR γδ T cell clinical trial at National University Hospital in Singapore, having received regulatory approval, marking a significant advancement in the company's cancer immunotherapy efforts, which is expected to drive further development of its product pipeline.
- Technological Focus: The company is focused on developing CAR γδ T cell and iPSC-derived γδ NKT cell therapies to address treatment needs for both blood and solid tumors, showcasing its innovative potential in the biopharmaceutical sector.
- Rebuttal of False Claims: CytoMed strongly rejects inaccurate statements regarding its research status and regulatory standing, emphasizing its commitment to compliance and transparency to protect shareholder interests and the company's reputation.
- Future Outlook: Despite external challenges, CytoMed remains dedicated to advancing its research pipeline and communicating accurate information through official channels, ensuring investor confidence in the company's future development.
Continue Reading
CytoMed Enters MOU with UMMC for First-in-Human Cancer Trial
- Trial Collaboration Initiated: CytoMed has signed a Memorandum of Understanding with Universiti Malaya Medical Centre to conduct a multi-site first-in-human Phase I clinical trial, aimed at evaluating the safety and efficacy of its patented γδ T cell therapy for no-option cancer patients, marking a strategic expansion into the Southeast Asian market.
- Technological Advantage: By utilizing donor-derived γδ T cells, CytoMed's therapy circumvents the high costs and logistical complexities associated with autologous treatments, making cancer immunotherapy more accessible and potentially providing a cost-effective option for Malaysian patients.
- Clinical Research Backing: Collaborative research with MD Anderson Cancer Center has demonstrated the potential of γδ T cells in treating acute myeloid leukemia, further solidifying the scientific foundation for CytoMed's clinical trials and driving innovation in cancer treatment.
- Broad Market Potential: This partnership with UMMC not only underscores CytoMed's commitment to emerging markets but also facilitates business growth in Southeast Asia, addressing the increasing demand for cancer therapies and enhancing the company's competitiveness in the global biopharmaceutical industry.
Continue Reading